Findings presented at SABCS from largest intrinsic subtype analysis show Kisqali is unique among CDK4/6 inhibitors, delivers consistent efficacy across main HR+/HER2- intrinsic subtypes1 Benefit seen even in patients with the endocrine-resistant HER2-enriched subtype, who face poor prognosis with endocrine therapy alone, reinforces Kisqali as first line treatment choice for all patients2 Data presented at… Continue reading Novartis Kisqali® data demonstrate superior benefit across main intrinsic subtypes in metastatic breast cancer
MONALEESA-7 median overall survival (OS) results reinforce Kisqali as the CDK4/6 inhibitor with unrivaled OS evidence1 Kisqali plus endocrine therapy had a median OS of nearly five years (58.7 months), the longest ever reported for premenopausal women with HR+/HER2- metastatic breast cancer (MBC), after a median of 53.5 months follow-up1 Kisqali offers the chance for… Continue reading Novartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancer
At 24 weeks, asciminib nearly doubled the major molecular response (MMR) rate compared to Bosulif® (bosutinib)*, in patients resistant to, or intolerant of, at least two prior tyrosine kinase inhibitor (TKI) therapies1 Despite advances in chronic myeloid leukemia (CML) care, many patients are at risk of disease progression, and sequential TKI therapy may be associated… Continue reading Novartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif®* in chronic myeloid leukemia trial
Five virtual power purchase agreements (VPPAs) with three developers expected to add more than 275 megawatts of clean power to the electrical grid Projects expected to address Novartis greenhouse gas emissions across its European operations, equivalent to removing approximately 113 000 passenger vehicles from the road annually1 Agreements mark a major milestone on the Novartis… Continue reading Novartis set to achieve 100% renewable electricity in its European operations
Post hoc EXPAND analysis showed improvements in cognitive processing speed in patients with active and non-active SPMS treated with Mayzent1 Subgroup analyses of the EXPAND trial showed the value of early treatment initiation with Mayzent in patients with active SPMS as positive effects on disability, cognitive processing speed and relapse outcomes were sustained for up… Continue reading Novartis data show early treatment with Mayzent® (siponimod) delays disability progression and show benefits in cognitive performance in patients with secondary progressive multiple sclerosis (SPMS)
Novartis will present 48 abstracts at the upcoming MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting, September 11–13, 2020. The breadth of data being presented highlights the strength and promise of the company’s MS portfolio to improve the lives of patients across the MS spectrum.
Novartis has reached settlements with the US Department of Justice (DOJ) and the US Securities and Exchange Commission (SEC) resolving all Foreign Corrupt Practices Act (FCPA) investigations into historical conduct by the Company and its subsidiaries. As part of the settlements, Novartis and certain of its current and former subsidiaries will pay USD 233.9 million to the DOJ and USD 112.8 million to the SEC.
US Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) for the treatment of active non-radiographic axial spondyloarthritis
Once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) met primary endpoint, demonstrating non-inferiority to a free combination of twice-daily Sal/Flu plus once-daily tiotropium (Tio), in improving quality of life in people with uncontrolled asthma
The U.S. FDA has notified Novartis that the agency has extended its review of the sBLA for subcutaneous ofatumumab in RMS.